The aim of the present meta-analysis was to evaluate the efficacy and safety of sapropterin dihydrochloride in phenylketonuria (PKU) patients.
into three main categories according to the severity of hyperphenylalaninemia (HPA): classic PKU (Phe > 1200 μmol L −1 ), mild PKU (Phe 600-1200 μmol L −1
) and mild HPA (Phe 120-600 μmol L −1 ). 3 Without treatment, toxic Phe concentrations may cause below-average IQ scores [4] [5] [6] and severe emotional dysfunction, 7 including attention deficit disorders, epilepsy and behavioural problems. 8 The basic treatment for PKU is low-phenylalanine diet. It is recommended that diet treatment should be started as early as possible 3 and continued through the whole life. 9 Although a severely restrictive diet is beneficial for PKU patients, long-term compliance is a tough challenge, especially for adolescents and those preparing for or during pregnancy. Early systematic reviews included only two randomized controlled trials (RCTs). 12, 13 With two more RCTs included, we conducted the present meta-analysis to quantitatively assess the efficacy and safety for PKU patients with different Phe blood levels.
| METHODS
This systematic review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 14, 15 The study protocol was registered in PROSPERO (CRD42018109725). 
| Search strategy

| Study selection
Eligibility criteria for study selection included: (1) RCTs; (2) patients 
| Data extraction and quality assessment
Using a data extraction form, details of study design, patient characteristics, interventions, control, and efficacy and safety outcomes were independently extracted by two authors. When detailed data were not reported in the publications, the corresponding author was contacted and clinicaltrials was visited to obtain additional information. When necessary, GetData Graph Digitizer (Version 2.26) was used to capture the data from figures. Two authors independently assessed the risk of bias of included trials using the Cochrane Risk of Bias tool. Studies are scored as either a low, unclear or high risk of bias in six domains: selection, performance, detection, attrition, reporting and other bias. 16 Differences in data extraction and assessment of bias were solved through meetings.
| Data synthesis and statistical analysis
Data was analysed using RevMan 5.3 software provided by the Cochrane Collaboration. Subgroup analysis was performed on the basis of the baseline Phe concentration. The overall effect size was
What is already known about this subject
• Two previous systematic reviews have demonstrated phenylketonuria patients may benefit from using sapropterin in the short term, with lowered blood phenylalanine (Phe) concentration and increased protein tolerance.
What this study adds
• We conducted a meta-analysis and stratified phenylketonuria patients according to the baseline blood phenylalanine concentration.
• For patients with low baseline Phe level, there was no difference in change of blood Phe concentration between sapropterin and Phe-restricted diet only.
However, sapropterin increased dietary Phe tolerance, making partial relaxation of dietary restrictions possible for patients.
• For patients with high baseline Phe level, sapropterin significantly reduced Phe concentration within 6 weeks.
As the follow-up period extended to Week 26, there was no difference between the sapropterin and control groups.
presented as the weighted mean difference (WMD) and 95% confidence intervals (CIs 
| Study selection and characteristics of included studies
The process of searching and identifying studies is reported in Figure 1 .
Four RCTs [19] [20] [21] [22] with 307 PKU patients met the inclusion criteria for the meta-analysis. The characteristics of eligible studies are summarized in Table 1 . The dose of saproterin ranged from 10 mg kg
. Four studies [19] [20] [21] [22] reported changes in blood Phe concentration. Two studies 21, 22 elaborated dietary Phe tolerance.
All studies reported adverse events. Individual RCT appraisal is reported in Figure 2 . Three of the studies had a high risk of reporting bias. As to attrition bias, all studies showed low risk.
| Change in blood Phe concentration
We stratified participants according to the severity of PKU at base- ; 95% CI: −312.28 to −138.34, P < 0.00001, I 2 = 0%; Figure 3 ). Figure 4 ).
| Change in dietary Phe tolerance
FIGURE 1 Study selection flow diagram
| Adverse events
We combined data for common adverse events reported in these four studies, including abdominal pain, diarrhoea, pyrexia, cough, vomiting, upper respiratory tract infection, headache and oropharyngeal pain. Table 2 shows a summary of the meta-analysis of these adverse events. There was no significant difference between groups. No serious adverse events were reported in the studies by Levy et al. 20 or Trefz et al. 22 Another two studies, Burton et al. 19 and Muntau et al., 21 reported a few serious adverse events (SAEs). However, none of these SAEs was deemed to be related to treatment or led to withdrawals.
| DISCUSSION
In this meta-analysis of four studies, we investigated the efficacy and , executive and cognitive function deteriorate.
Sapropterin reduced blood Phe concentration to normal range in a short time (within 6 weeks), which might minimize the risk of cognitive impairments.
Two retrospective cohort studies 30 
| CONCLUSION
Sapropterin could be beneficial for PKU patients with high or low Phe level due to Phe reduction in a short time or dietary Phe tolerance improvement, respectively. Sapropterin has an acceptable safety profile. Future research with larger sample sizes and longer-term follow-up is still needed to assess the efficacy and safety of sapropterin.
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